Oracle Investment Management Inc. In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Oracle Investment Management Inc. reported 11 stock positions worth $153.6 million . Its top holding was Genedx (WGS) at 55.9% of the portfolio, followed by Springworks Therapeutics (SWTX, 15.3% ) and Biohaven (BHVN, 10.4% ). Compared with Q4 2024, it opened 2 new positions, sold out of 4, added to 3 and reduced 2. The biggest buy was Springworks Therapeutics (SWTX, shares +109% ) and the biggest sale Biohaven (BHVN, shares −22% ).
Location GREENWICH, CT
CIK 0001012622
Portfolio Value $153.6M (Q1 2025) Holdings 11 stocks · $153.6M Holdings quarter Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q4 2024 WGS Genedx Holdings Corp. 969,954 $85.9M Reduce -5.2% SWTX Springworks Therapeutics Inc. 531,351 $23.4M Add +108.6% BHVN Biohaven Ltd. 665,945 $16.0M Reduce -21.8% ARDX Ardelyx Inc. 2,404,438 $11.8M Add +15.1% TDOC Teladoc Health Inc. 565,900 $4.5M New QDEL Quidelortho Corp. 118,291 $4.1M No change FORA Forian Inc. 1,366,107 $2.7M No change PLTR Palantir Technologies Inc. Class A 29,500 $2.5M Add +3.5% CAVA Cava Group Inc. 18,600 $1.6M No change RXRX Recursion Pharmaceuticals-A 120,000 $635K New BIIB Biogen Inc. 2,412 $330K No change
Options reported separately and not counted above: SPDR SERIES TRUST calls ($22.7M), VIKING THERAPEUTICS INC calls ($8.1M), ARDELYX INC calls ($5.6M), BIOHAVEN LTD calls ($3.9M), PELOTON INTERACTIVE INC calls ($3.2M), TELADOC HEALTH INC calls ($1.1M).
Portfolio Sells Q4 2024 → Q1 2025 Portfolio Sells quarter Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2024 % Of Portfolio Change To Portfolio ▲ BHVN Biohaven Ltd. Reduce -21.8% 10.42% −10.94 BCRX Biocryst Pharmaceuticals Inc. Sold out 0.00% −2.70 PHAT Phathom Pharmaceuticals Inc. Sold out 0.00% −0.79 PACB Pacific Biosciences of Calif Sold out 0.00% −0.34 EYPT Eyepoint Inc. Sold out 0.00% −0.16 WGS Genedx Holdings Corp. Reduce -5.2% 55.93% +3.11
Portfolio Buys Q4 2024 → Q1 2025 Portfolio Buys quarter Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2024 % Of Portfolio Change To Portfolio ▼ SWTX Springworks Therapeutics Inc. Add +108.6% 15.27% +9.09 TDOC Teladoc Health Inc. New 2.93% +2.93 ARDX Ardelyx Inc. Add +15.1% 7.69% +0.57 RXRX Recursion Pharmaceuticals-A New 0.41% +0.41 PLTR Palantir Technologies Inc. Class A Add +3.5% 1.62% +0.17
Options Activity Q4 2024 → Q1 2025 Security Type Change vs Q4 2024 Underlying Shares Value ▼ SPDR SERIES TRUST call New 280,000 $22.7M SELECT SECTOR SPDR TR put Sold out 115,000 $15.8Mbefore exit VIKING THERAPEUTICS INC call New 336,700 $8.1M ARDELYX INC call Add +93.9% 1,133,500 $5.6M BIOHAVEN LTD call Reduce -19.1% 161,900 $3.9M NOVAVAX INC call Sold out 466,000 $3.7Mbefore exit PELOTON INTERACTIVE INC call New 500,000 $3.2M SPRINGWORKS THERAPEUTICS INC call Sold out 55,800 $2.0Mbefore exit TELADOC HEALTH INC call Reduce -51.5% 144,300 $1.1M
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q4 2025 17 $152.6M WGS, ARDX, BHVN, QDEL, FORA Q3 2025 16 $143.3M WGS, BHVN, ARDX, TDOC, PLTR Q2 2025 9 $115.6M WGS, BHVN, ARDX, PLTR, QDEL Q1 2025 11 $153.6M WGS, SWTX, BHVN, ARDX, TDOC Q4 2024 13 $148.9M WGS, BHVN, ARDX, SWTX, QDEL Q3 2024 15 $125.1M WGS, BHVN, PHAT, ARDX, QDEL Q2 2024 16 $93.2M WGS, BHVN, ARDX, SWTX, QDEL Q1 2024 18 $124.2M BHVN, SWTX, ARDX, WGS, EYPT